Hepatocellular carcinoma: metastatic pathways and extra-hepatic findings
- Resource Type
- Authors
- Sandeep Arora; Carla Harmath; Roberta Catania; Kathryn J. Fowler; Ari G. Mandler; Amir A. Borhani
- Source
- Abdominal Radiology. 46:3698-3707
- Subject
- Oncology
medicine.medical_specialty
Radiological and Ultrasound Technology
Tumor biology
business.industry
Urology
Gastroenterology
Treatment options
Disease
Hepatology
medicine.disease
digestive system diseases
030218 nuclear medicine & medical imaging
Metastasis
03 medical and health sciences
0302 clinical medicine
030220 oncology & carcinogenesis
Hepatocellular carcinoma
Internal medicine
medicine
Radiology, Nuclear Medicine and imaging
In patient
business
- Language
- ISSN
- 2366-0058
2366-004X
Although a small portion of patients with hepatocellular carcinoma (HCC) have radiologically evident extrahepatic disease at the initial presentation, a larger number of them develop metastatic disease later during the course of treatment or after definitive treatment. Furthermore, early metastatic disease could be overlooked by imaging due to small size and non-specificity of findings. Extrahepatic spread of HCC occurs via different pathways and is directly fueled by tumor biology and its molecular characteristics. Early and accurate detection of extrahepatic disease in patients with HCC has significant impact on management and selection of treatment options. Additionally, precise staging of disease will allow for better prediction of survival and outcome. Different pathways of regional and systemic spread of HCC with their proposed mechanisms and relevant underlying molecular derangement will be discussed in this article. Potential roles in management of patients with HCC will be discussed and reviewed in this article.